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Abstract Double strand DNA breaks are the most dangerous
DNA damage which, if non-repaired or misrepaired, may re-
sult in genomic instability, cancer transformation or cell death.
RAD51 and XRCC2 encode proteins that are important for the
repair of double-strand DNA breaks by homologous recombi-
nation. Therefore, genetic variability in these genes may con-
tribute to the occurrence and progression of triple-negative
breast cancer. The polymorphisms of the XRCC2 gene -
41657C/T (rs718282) and of the RAD51 gene, −172G/T
(rs1801321), were investigated by PCR-RFLP in 70 patients
with triple-negative breast cancer and 70 age- and sex
matched non-cancer controls. The obtained results demon-
strated a significant positive association between the RAD51
T/T genotype and TNBC, with an adjusted odds ratio (OR) of
4.94 (p=0.001). The homozygous T/T genotype was found in
60% of TNBC cases and in 14% of the used controls. Variant
172 Tallele of RAD51 increased cancer risk (OR=2.81 (1.72–
4.58), p<.0001). No significant associations were observed
between -41657C/T genotype of XRCC2 and the incidence
of TNBC. There were no significant differences between the
distribution of XRCC2 -41657C/T genotypes in the subgroups
assigned to histological grades. The obtained results indicate
that the polymorphism of RAD51, but not of XRCC2 gene,
may be positively associated with the incidence of triple-
negative breast carcinoma in the population of Polish women.
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Introduction
Triple-negative breast cancer (TNBC) is a subtype of breast
cancer defined by the lack of expression of estrogen, proges-
terone and HER-2 (human epidermal receptor-2) receptors.
TNBC refers to about 15–20 % of all breast cancer cases. It
is characterised by worse clinical outcome, poor prognosis
and absence of prognostic indicators [1–5].
Mutations in DNA of double-strand breaks (DSB) repair
genes are involved in the pathogenesis of tumours, however, it
is still unclear whether any defects in this pathway may play
any role in the aetiology of triple-negative breast cancer.
DSB in DNA may be rectified either by homologous re-
combination (HR) or non-homologous end joining (NHEJ) [6,
7].
RAD51 is involved in the homologous recombination and
repair of double-strand breaks in DNA and DNA cross-links
and is responsible for the maintenance of chromosome stabil-
ity [8].
RAD51 gene has been mapped to chromosome 15q14-15
and is polymorphic in nature. The involvement of RAD51 in
the DNA repair determines its potential role in maintaining
genetic stability, which is disturbed in cancer. Therefore the
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problem of genetic variability of the RAD51 gene in cancer is
worthy studying. A substitution G/T at position 172 in 5′ un-
translated region of the RAD51 gene (the 172G/T 5′UTR poly-
morphism) has been reported as a possible factor to affect the
RAD51 mRNA stability [8, 9]. 172G/T polymorphism of
RAD51 is located in the regulatory element of the RAD51
promoter and is suggested to be associated with messenger
RNA expression [8, 9].
In literature, many of researches suggest that 5′UTR poly-
morphism of RAD51 gene may contribute to mammary carci-
nogenesis. However, the reported results have rather been in-
consistent [10–16].
XRCC2 gene, located in 7q36.1, is an essential part of the
homologous recombination repair pathway and a functional
candidate for involvement in cancer progression [17].
It is known that polymorphisms in XRCC2 may modify
individual susceptibility to breast cancers [13, 14, 18–20].
Common variants within XRCC2, particularly a coding single
nucleotide polymorphism (SNP) in exon 3 (Arg188His,
R188H, rs3218536), have in recent studies been identified
may be associated with a significantly increased risk of breast
cancer [13, 14, 18–20].
Unfortunately, it is difficult to find in the literature reports
directly binding -41657C/T SNP in DNA repair gene XRCC2
with breast cancer occurrence.
Because little is known on the association between RAD51-
172G/T and XRCC2-41657C/T polymorphisms and TNBC, it
was studied whether the polymorphisms in the two genes,
being involved in the homologous recombination of double-
strand breaks, could have been linked with the risk for triple-
negative breast cancer in that Polish population.
Materials and Methods
Patients with Triple- Negative Breast Cancer
A total of 70 patients with histologically-proven diagnosis
of TNBC were included in the reported study. The distri-
butions of sociodemographic characteristics, lifestyle risk
factors and clinical characteristics of the patients are
shown in Tables 1 and 2, respectively. Paraffin embedded
tumour tissue specimens were obtained from women with
triple-negative breast carcinoma, treated at the Depart-
ment of Oncology, Institute of Polish Mothers Memorial
Hospital, between 2000–2013. The age of the patients
ranged in from 36 to 68 years (the mean age 46.2±
10.12). The median follow-up of patients at the time of
analysis was 38 months (the range: 2–70 months). The
average tumor size was 20 mm (the range 17–32 mm).
All the diagnosed tumours were graded by criteria of the
Scarf-Bloom-Richardson. DNA from non-cancerous
breast tissue (n=70) served as control (mean age 45.41±
Table 1 Characteristics of breast cancer patientsa with questionnaire
data






Family history of breast cancerb
Yes 25 (36)
No 45 (64)




































b Family history defined as self-reporting of at least one first-degree rel-
ative with known breast cancer
c Non-smoking patients (never), patients smoking 10 cigarettes per day
for 10 years (ever), patients smoking 20 cigarettes per day for 20 years
(moderate) and patients smoking 20 cigarettes per day for thirty years
(heavy)
d Never/rare,<1 U/week; light, 1–8.9 U/week; moderate, 9–17.9 U/week;
heavy, ≥18 U/week; where 1 U=22 g ethanol
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18.21). The Local Ethical Committee approved the study
and each patient gave a written consent for participation
in the study.
Breast tissue samples (cancerous and non-cancerous) were
routinely fixed in phormaldehyde, embedded in paraffin, cut
into thin slices and stained with haematoxylin/eozin for path-
ological examination. DNA for analysis was obtained from
archival pathological paraffin-embedded tumour specimens
and from samples of non-cancerous breast tissue, which were
deparaffinised in xylene and rehydratated in ethanol and dis-
tilled water. In order to ensure that the chosen histological
material was representative for cancerous and non-cancerous
tissue, each tissue sample, qualified for DNA extraction, was
initially checked by a pathologist. DNA was extracted from
the material, using a commercially available QIAmp DNA
purification kit (Qiagen GmbH, Hilden, Germany), according
to the manufacturer’s instruction.
Genotype Determination
The PCR- restriction fragment length polymorphism method
(PCR-RFLP) was used to detect the genotypes of the -
41657C/T and -172G/T polymorphisms as described previ-
ously [21–23].
Statistical Analysis
For each polymorphism, departure of the genotype distribu-
tion from that expected from Hardy-Weinberg equilibrium
was assessed using the standardχ2-test. Genotype frequencies
in the study cases and the controls were compared by χ2-test.
Genotype specific risks were estimated as odds ratios (ORs)
with associated 95 % intervals (CIs) by unconditional logistic
regression. P-values<0.05 were considered significant. All
the statistical analyses were performed, using the STAT
ISTICA 6.0 software (Statsoft, Tulsa, Oklahoma, USA).
Results
Table 3 shows genotype distribution of RAD51 polymor-
phism, illustrating the difference between the patients with
TNBC and the controls. The Table clearly indicates significant
differences (p<0.05) between the two investigated groups. A
weak association was observed between the occurrence of
triple-negative breast carcinoma and the presence of G/T and
T/T genotypes. A stronger association was observed for T/T
homozygotes than for G/T heterozygotes. Variant 172 T allele
of RAD51 increased cancer risk. The frequencies of G/G, G/T
and T/T genotypes, observed in the study patients, differed
significantly (p<0.05) from the distribution values, as expect-
ed from the Hardy-Weinberg equilibrium.
Table 2 Characteristic features of triple-negative breast cancer
patientsa






















172G/T Number (%) Number (%) OR (95 % CI)a pb
G/G 17 24 20 29 1.00 Ref
G/T 11 16 40 57 0.32 (0.13–0.82) 0.028
T/T 42 60 10 14 4.94 (1.91–12.71) 0.001
G 45 32 80 57 1.00 Ref
T 95 68 60 43 2.81 (1.72–4.58) <.0001
Data in bold font are statistically significant
a Crude odds ratio (OR), 95 % CI=confidence interval at 95 %
bChi square
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No statistically significant differences were observed be-
tween the control group and the patients with triple-negative
breast cancer, regarding either allele or genotype frequencies
of XRCC2 -41657C/T gene polymorphism (see Table 4).
Scarf-Bloom-Richardson grading was related to RAD51
and XRCC2 polymorphisms. Histological grade was evaluat-
ed in all the cases (n=70), where 20 cases were of grade I, 45
of grade II and 5 of grade III. Grade II and III were grouped
together for the purposes of statistical analysis (see Table 5).
No differences were observed in those groups between
RAD51 and XRCC2 genotype distributions, while a lack of
correlation was demonstrated between genotypes of the iden-
tified polymorphisms and TNBC invasiveness.
We did not find any association of the XRCC2 and RAD51
polymorphisms in patients group with cancer progression
assessed by breast cancer with (N+) and without (N-) lymph
node metastases (p>0.05). Our data did not demonstrate any
statistically significant correlation between RAD51 and
XRCC2 polymorphisms and the risk factors for breast cancer,
such as BMI (body mass index), smoking status, alcohol con-
sumption, menarche, menopause status, reproductive histo-
ries, exogenous hormone use and medical history (data not
shown).
Discussion
Breast cancer classification is in constant evolution, as ad-
vances in molecular pathology as well as immunohistochem-
ical staining allow researchers to define the molecular
heterogenity of different disease subtypes and to guide the
selection of appropriate treatment. The triple negative pheno-
type, defined as the lack of estrogen receptor, progesterone
receptor and HER-2 expression, represents approximately
15-20 % of breast cancer cases and has a worse clinical out-
come and prognosis than other breast cancer subtypes [1–5].
As it has already been mentioned above, little is known on
the association between the homologous recombination repair
RAD51 and XRCC2 SNPs and triple-negative breast cancer.
Therefore, it was attempted to investigate the role of genetic
variation in homologous recombination repair genes and the
risk of TNBC.
As mentioned in Introduction mutations in DNA double-
strand breaks repair genes are involved in the pathogenesis of
tumours. Defects in this pathway may play a role in develop-
ment and progression of breast cancer [24, 25].
In the literature, many reports confirm the significance
RAD51 gene polymorphisms in the 5′UTR, regarding the risk
of breast carcinoma [16, 26–28]. However, the reported results
have rather been inconsistent [10–16].
No significant associations were observed between the
172G/T and breast cancer in Korean women. The genotype
distributions of RAD51 SNP did not differ significantly from
Hardy-Weinberg equilibrium (P>0.05) and the frequencies of
minor alleles were 0.13 for RAD51 135C and 0.05 for RAD51
172 T. When the two loci in the same gene were evaluated for





−41657C/T Number (%) Number (%) OR (95 % CI)c pb
C/C 18 26 17 24 1.00 Ref
C/T 35 50 37 53 0.89 (0.39–2.00) 1.000
T/T 17 24 16 23 1.00 (0.38–2.59) 0.806
C 71 51 71 51 1.00 Ref
T 69 49 69 49 1.00 (0.62–1.59) 0.920
a Crude odds ratio (OR), 95 % CI confidence interval at 95 %
bChi square
Table 5 Dependence of RAD51 and XRCC2 gene polymorphism
genotypes and allele frequency on tumour grade in patients with triple–
negative breast cancera
gradeb I (n=20) II+III (n=50) OR (95 % CI)c pd
RAD51 172G/T Number (%) Number (%)
G/G 4 (20 %) 13 (26 %) 1.00 Ref
G/C 2 (10 %) 9 (18 %) 0.72 (0.10–4.82) 0.560
C/C 14 (70 %) 28 (56 %) 1.62 (0.44–5.91) 0.671
G 10 (25 %) 35 (35 %) 1.00 Ref
C 30 (75 %) 65 (65 %) 1.61 (0.70–3.68) 0.345
XRCC2 41657C/T
C/C 4 (20 %) 14 (28 %) 1.00 Ref
C/T 14 (70 %) 21 (42 %) 1.19 (0.33–4.23) 0.526
T/T 2 (10 %) 15 (30 %) 0.47 (0.07–2.95) 0.357
C 22 (55 %) 49 (49 %) 1.00 Ref
T 18 (45 %) 51 (51 %) 0.79 (0.37–1.64) 0.647
a n=70
b according to Scarf-Bloom-Richardson criteria
c Crude odds ratio (OR), 95 % CI confidence interval at 95 %
dChi square
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linkage disequilibrium, two loci in RAD51 gene (135G/C and
171G/T) were in negative linkage disequilibrium [15].
Shin et al. examined the role of SNPs in RAD51 repair
genes and the risk of breast cancer. In the reported study,
the 135G/C but not 172G/T polymorphism, of RAD51
gene, was associated with breast carcinoma occurrence
[16].
Other experimental study confirms the significance RAD51
gene G135C polymorphism, regarding the risk of breast car-
cinoma [10–14].
The role of -41657C/T variation of XRCC2 in breast cancer
is still unknown. Some reports documented that the XRCC2 -
41657C/T genotype was related to increased esophageal squa-
mous cell carcinoma (ESCC), gastric cardia adenocarcinoma
(GCA) and in smoking- drinking-related laryngeal cancer risk
[22, 29].
It appears from literature review that RAD51 and XRCC2
polymorphisms have been investigated in various types of
malignancy. A large number of studies confirm a significant
role of the influence of specific genetic variants on repair
phenotype and cancer risk [29–34].
Unfortunately, it is difficult to find reports in the available
literature, which would directly bind RAD51 and XRCC2 SNP
in DNA repair gene by HR with clinical-pathological features
of breast tumour. Only in single studies the researchers sug-
gest that the homologous recombination repair gene polymor-
phism may play some role in the development of breast car-
cinoma [13].
Two single nucleotide polymorphisms of XRCC2-41657C/
T, and RAD51-172G/Twere investigated in the reported study,
as well as their association with human triple- negative breast
cancer.
In literature, neither XRCC2-41657C/T nor RAD51-172G/
T polymorphism is correlated with risk of breast cancer [15,
16]. What are important, recent reports introduce the role of
RAD51 135G/C polymorphism in the development of triple-
negative breast cancer [27].
In the recent studies, 135G/C polymorphism of RAD51
may be associated with an elevated tumour risk in the Polish
populations, regarding TNBC [28], while there are still no
data, which would be illustrating the significance of RAD51
polymorphism for triple-negative breast cancer development
in other populations.
The obtained results confirm the important role of RAD51
G172T polymorphism for TNBC occurrence in Poland. In the
reported study, RAD51 T/T genotype increased the risk of
breast cancer in the Polish population. There was a 4.94-fold
increased risk of breast carcinoma for RAD51-T/T genotype
carriers, compared with subjects with RAD51-G/G, G/T geno-
type. The 172 T allele increased the risk of TNBC. RAD51
G172T polymorphism was not related to cancer grade. It is
possible that the presence of the 172 T allele is in some dis-
equilibrium with another, so far unknown, mutation, located
outside the coding region in RAD51 gene, which may be of
importance for RAD51 concentration in plasma.
No significant associations were observed between -
41657C/T genotype of XRCC2 and the incidence of TNBC
in the Polish women.
In conclusion, the obtained data confirm the important role
of RAD51 172G/T - but not of -41657C/T of XRCC2 gene
polymorphism in triple-negative breast cancer aetiology.
Finally, we suggest that RAD51 172G/T may be used as a
prognosing factor of precancerous lesions, predicting TNBC
in the Polish population. Further studies are required, regard-
ing the role of these genes in the aetiology of triple-negative
breast cancer.
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